# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

> **NCT06680440** · PHASE1 · COMPLETED · sponsor: **Ascletis Pharma (China) Co., Limited** · enrollment: 72 (actual)

## Conditions studied

- Weight Management

## Interventions

- **DRUG:** ASC30
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06680440
- **Lead sponsor:** Ascletis Pharma (China) Co., Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-26
- **Primary completion:** 2025-04-03
- **Final completion:** 2025-04-03
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06680440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06680440, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06680440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*